Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population

NCT04019808 | Completed

• 1 other identifier: LEGACY-3
• Study Type: observational
• Target: 800
• Locations: 7 countries
• Sites: 8

Brief Summary

This study is divided into two parts: Part 1: An interventional study, with a pre-post study design to determinate the grade of knowledge of established GC risk factors. Part 2: An observational study to know impact on prevalence and infection eradication of H. pylori

Conditions

Gastric Cancer

Keywords

Gastric Cancer; Personalized medicine; Oncology; Solid tumor; Primary Intervention

Outcome Measures

Primary Outcomes (2)

• knowledge GC risk factors and symptoms

  Compare the results obtained through a knowledge of CG risk factors by study-specific questionnaire before and after an educational intervention

  3 years

• H. pylori prevalence and drug resistance

  Generate an H. pylori registry, to know its impact on prevalence and infection eradication rate at months 6th, 12th, 24th and 36th.

  3 years

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Part 1: Subjects \>18 years old whom able to answer the questions structured in the survey. Part 2: Subjects \>18 years old diagnose from H. pylori infection

You may qualify if:

• Subjects \>18 years old, from EU and CELAC countries participating in this study.

You may not qualify if:

• Subjects who have received some prior preparation (Cancer Gastric Information).
• Subjects who have previous Knowledge in Gastric Cancer (Example, near relatives who have suffered Gastric Cancer
• Subjects ≥18 years old diagnose from H. pylori infection and treated at participant sites
• Subjects with chronic gastritis without confirmed diagnose of H. pylori infection, pathologically of by urease test.
• Patient's with CG diagnosis (including gastroesophageal junction cancer).

Sponsors & Collaborators

• Fundación para la Investigación del Hospital Clínico de Valencia: lead
• Instituto Nacional de Cancerologia de Mexico: collaborator
• Amsterdam UMC, location VUmc: collaborator
• Pontificia Universidad Catolica de Chile: collaborator
• Vall d'Hebron Institute of Oncology: collaborator
• INSTITUTO ALEXANDER FLEMING: collaborator
• Hospital Central del IPS: collaborator
• IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto: collaborator

Study Sites (8)

Instituto Alexander Fleming

Buenos Aires, C1426NZ, Argentina

Location

Pontificia Universidad Católica de Chile

Santiago, 8331150, Chile

Location

Instituto Nacional de Cancerología

México, 01480, Mexico

Location

VU Medical Centre

Amsterdam, 1081, Netherlands

Location

GenPat

Asunción, Paraguay

Location

Institute of Pathology and Immunology of University of Porto

Porto, 4200 135, Portugal

Location

Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (VHIO)

Barcelona, 08035, Spain

Location

Fundación Investigación Clínico de Valencia

Valencia, 46010, Spain

Location

Related Publications (2)

• Carbonell-Asins JA, Jimenez-Marti E, Romero S, Garcia E, Miralles-Marco A, Lopez B, Huerta M, Caballero C, Boggino H, Gauna C, Acevedo-Funes OB, Nunez GB, Cespedes-Cardozo CM, Fernandez-Figueroa EA, Ortiz-Olvera N, Ruiz-Garcia E, Carneiro F, Barros R, Figueiredo C, Ferreira RM, Groen-van Schooten TS, van Santvliet D, Derks S, Luca R, Alsina M, Riquelme A, Cervantes A, Fleitas T. Implementation of an Educational Intervention for Gastric Cancer Awareness in the General Population in CELAC and Europe: A Strategy Proposed by the LEGACy Consortium. J Cancer Educ. 2025 Oct;40(5):804-811. doi: 10.1007/s13187-025-02578-2. Epub 2025 Feb 13.

  PMID: 39939517 DERIVED

• van Schooten TS, Derks S, Jimenez-Marti E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O'Connor JM, Esteso F, Farres J, Mas JM, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T; members of LEGACy consortium. The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. BMC Cancer. 2022 Jun 13;22(1):646. doi: 10.1186/s12885-022-09689-9.

  PMID: 35692051 DERIVED

MeSH Terms

Conditions

Stomach Neoplasms; Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 5, 2019
• First Posted: July 15, 2019
• Study Start: July 30, 2019
• Primary Completion: December 31, 2023
• Study Completion: December 31, 2023
• Last Updated: May 9, 2024

Record last verified: 2024-05

Locations

AR (1); CL (1); ME (1); NL (1); PT (1); PA (1); ES (2)